Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).

26 Jul 2012

Cepheid launches new Xpert BCR-ABL Monitor test

Cepheid today announced the release of an updated Xpert BCR-ABL Monitor test, now incorporating lot-specific standardization using the WHO (World Health Organization) BCR-ABL standards.

25 Jul 2012

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Janssen-Cilag International NV announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of DACOGEN (decitabine) for Injection.

21 Jul 2012

Study helps explain why leukemia occurs more frequently as people age

Hundreds of mutations exist in leukemia cells at the time of diagnosis, but nearly all occur randomly as a part of normal aging and are not related to cancer, new research shows.

20 Jul 2012

Actinium completes Actimab-A Phase I/II study on Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City.

20 Jul 2012

Three outstanding young scientists named July 2012 Damon Runyon-Sohn Fellows

The Damon Runyon Cancer Research Foundation and the Sohn Conference Foundation have named three outstanding young scientists as the first-ever Damon Runyon-Sohn Pediatric Cancer Research Fellows, committing more than half a million dollars to help address a critical shortage of funding for pediatric cancer research.

18 Jul 2012

Targeting CDK1 pathway may be efficacious for acute myeloid leukemias with FLT3 mutation

Acute myeloid leukemia, a common leukemia in adults, is characterized by aberrant proliferation of cancerous bone marrow cells. Activating mutations in a protein receptor known as FLT3 receptor are among the most prevalent mutations observed in acute myeloid leukemias. FLT3 mutants are thought to activate several signaling pathways that contribute to cancer development.

17 Jul 2012

IDH mutation drives aggressive form of acute myeloid leukemia

Many patients with acute myeloid leukemia (AML) share a mutation in a gene called IDH. A University of Colorado Cancer Center study published this week in the journal Leukemia & Lymphoma shows that this IDH mutation may be the first domino in a chain that leads to a more aggressive form of the disease.

16 Jul 2012

Maraviroc reduces incidence of GvHD in blood cancer patients after bone marrow transplantation

An HIV drug that redirects immune cell traffic significantly reduces the incidence of a dangerous complication that often follows bone marrow transplants for blood cancer patients, according to research from the Perelman School of Medicine at the University of Pennsylvania that will be published today in the New England Journal of Medicine.

12 Jul 2012

DRCRF names 21 new Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 21 new Damon Runyon Fellows at its spring Fellowship Award Committee review.

11 Jul 2012

Insight into understanding IDH mediated disease

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in cancer metabolism, announced today the publication of a new study that provides further evidence of the link between a mutated metabolic enzyme and acute myeloid leukemia (AML), one of the most common types of leukemia in adults.

6 Jul 2012

Scientists identify causative link between oncometabolite and onset of AML

A team of international scientists led by principal investigator Dr. Tak Mak at the Princess Margaret Cancer Centre, University Health Network, has identified a causative link between the product of a mutated metabolic enzyme and the onset of acute myeloid leukemia (AML), one of the most common types of leukemia in adults.

5 Jul 2012

Abnormal bone marrow stem cells drive development of myelodysplastic syndromes

Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among the elderly and that can progress to acute leukemia. The findings could lead to targeted therapies against MDS and prevent MDS-related cancers. The study is published today in the online edition of the journal Blood.

2 Jul 2012

CHLA pediatric oncologist receives Hyundai Hope on Wheels grant

Weili Sun, MD, PhD, a pediatric oncologist at Children's Hospital Los Angeles, was awarded $75,000 by the Hyundai Hope on Wheels program. She will use this money to further her research into the role of epigenetics in cancer.

28 Jun 2012

KPT-SINEs might offer new treatment for people with acute leukemia

A novel family of experimental agents that blocks a molecule from shuttling proteins out of the cell nucleus might offer a new treatment for people with acute leukemia, according to a study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

20 Jun 2012

UW initiates enrollment in tosedostat phase II combination study for AML, MDS

Cell Therapeutics, Inc. today announced that the University of Washington has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome.

18 Jun 2012

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec (imatinib).

16 Jun 2012

Strand, Trovagene enter MOU to license and validate HPV assay technology

Trovagene, Inc., a developer of trans-renal molecular diagnostics, and Strand Life Sciences Pvt Ltd., of Bangalore, India, have entered into a Memorandum of Understanding (MOU) to license and validate Trovagene's proprietary Human Papillomavirus (HPV) urine test and High Risk HPV DNA Assay for clinical diagnostic and carrier screening use in India and countries in the South Asian Association for Regional Cooperation.

8 Jun 2012

$Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML$

Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML

Astellas Pharma Inc. and Ambit Biosciences Corporation today announced the initiation of a Phase 2b open-label clinical trial of quizartinib as monotherapy in patients with relapsed and refractory acute myeloid leukemia (AML) with FLT3-ITD mutations.

5 Jun 2012